Subtype
Malignant Male Reproductive System Neoplasm
CI-CAN-00003180Explore in graph →
1,451 active trials27 approved drugs58 evidence items
- NCIt
- C8561
Loading cancer entity…
Subtype
CI-CAN-00003180Explore in graph →
Clinical trials
6,225 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (762)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06604442 | Intrapatient Comparison of Urinary Radioactivity Following Piflufolastat (18F) and Flotufolastat (18F) PET in Men With Low PSA Biochemical Recurrence of Prostate Cancer Following Radical Prostatectomy | completed | Phase 4 | 62 | Blue Earth DiagnosticsINDUSTRY | 1 | Jul 13, 2026 | clinicaltrials |
| NCT03641560 | A Safety and Efficacy Study of Enzalutamide in Indian Patients With Progressive Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated With Docetaxel-Based Chemotherapy | completed | Phase 4 | 52 | Astellas Pharma IncINDUSTRY |
| 1 |
| Jun 24, 2026 |
| clinicaltrials |
| NCT02651948 | Transperineal, MRI-guided, Prostate Biopsy | completed | Phase 4 | 90 | University Hospital, Strasbourg, FranceOTHER | 1 | Dec 19, 2025 | clinicaltrials |
| NCT02405858 | A Study of Abiraterone Acetate in Metastatic Castration-Resistant Prostate Cancer Participants Who Responded Poorly to the First-line Combined Androgen Blockade Therapy | completed | Phase 4 | 51 | Janssen Pharmaceutical K.K.INDUSTRY | 1 | Feb 3, 2025 | clinicaltrials |
| NCT02918968 | Study on Enzalutamide and Flutamide in Patients With Castration Resistant Prostate Cancer | completed | Phase 4 | 206 | Astellas Pharma IncINDUSTRY | 1 | Dec 9, 2024 | clinicaltrials |
| NCT01977651 | A Study to Evaluate the Potential Increased Risk of Seizures Among Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated With Enzalutamide(UPWARD) | completed | Phase 4 | 424 | Astellas Pharma Global Development, Inc.INDUSTRY | 20 | Dec 6, 2024 | clinicaltrials |
| NCT02116582 | A Study to Evaluate Enzalutamide After Abiraterone in Metastatic Castration-Resistant Prostate Cancer | completed | Phase 4 | 215 | Astellas Pharma Europe B.V.INDUSTRY | 5 | Dec 6, 2024 | clinicaltrials |
| NCT03035032 | A Study of ELIGARD® in Hormone-dependent Prostate Cancer Patients | completed | Phase 4 | 107 | Astellas Pharma Singapore Pte. Ltd.INDUSTRY | 8 | Nov 26, 2024 | clinicaltrials |
| NCT01794793 | Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies | completed | Phase 4 | 337 | RECORDATI GROUPINDUSTRY | 28 | Oct 1, 2024 | clinicaltrials |
| NCT00953277 | Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer | completed | Phase 4 | 12 | Axogen CorporationINDUSTRY | 1 | Aug 12, 2024 | clinicaltrials |
| NCT01641172 | Taste, Smell and Chemotherapy (TASTY)(TASTY) | completed | Phase 4 | 140 | University Medical Center GroningenOTHER | 1 | Apr 19, 2024 | clinicaltrials |
| NCT05803096 | Self-Administered Nitrous Oxide (SANO) During Transrectal Prostate Biopsy to Reduce Patient Anxiety and Pain | completed | Phase 4 | 143 | Beth Israel Deaconess Medical CenterOTHER | 1 | Jan 30, 2024 | clinicaltrials |
| NCT01995513 | Safety Study of Continued Enzalutamide Treatment In Prostate Cancer Patients(PLATO) | completed | Phase 4 | 509 | PfizerINDUSTRY | 11 | Sep 18, 2023 | clinicaltrials |
| NCT03228108 | Culture-guided Antimicrobial Prophylaxis in Men Undergoing Prostate Biopsy.(pro-SWAP) | completed | Phase 4 | 1,538 | Radboud University Medical CenterOTHER | 1 | May 10, 2022 | clinicaltrials |
| NCT05304169 | Study to Evaluate the Safety and Efficacy of Switching From Zoladex® Monthly or Quarterly, to Eligard® Semiannual.(PRIZE) | completed | Phase 4 | 48 | Zodiac Produtos Farmaceuticos S.A.INDUSTRY | 1 | Mar 31, 2022 | clinicaltrials |
| NCT02726009 | A Trial to Evaluate Safety of Firmagon® (Degarelix) in Indian Patients Diagnosed With Advanced Hormone-dependent Prostate Cancer | completed | Phase 4 | 230 | Ferring PharmaceuticalsINDUSTRY | 1 | Dec 15, 2021 | clinicaltrials |
| NCT01753297 | A Study of Immediate 9 Months Adjuvant Hormone Therapy With Triptorelin 11.25 mg Versus Active Surveillance After Radical Prostatectomy in High Risk Prostate Cancer Patients.(PRIORITI) | completed | Phase 4 | 226 | IpsenINDUSTRY | 2 | Dec 9, 2020 | clinicaltrials |
| NCT02721433 | 4-weekly Versus 12-weekly Administration of Bone-targeted Agents in Patients With Bone Metastases(REaCT-BTA) | completed | Phase 4 | 263 | Ottawa Hospital Research InstituteOTHER | 1 | Dec 2, 2020 | clinicaltrials |
| NCT02812186 | Deep Versus Moderate Neuromuscular Blockade During Laparoscopic Surgery | completed | Phase 4 | 79 | Stony Brook UniversityOTHER | 1 | Apr 8, 2020 | clinicaltrials |
| NCT01136226 | Evaluate Recovery of Testosterone for Patients Using Eligard(Eligard) | completed | Phase 4 | 42 | Chesapeake Urology Research AssociatesOTHER | 0 | Oct 24, 2018 | clinicaltrials |
| NCT02818816 | Preoperative Brimonidine on IOP of Patients Undergoing RALP(IOPsTBURG) | completed | Phase 4 | 26 | University Health Network, TorontoOTHER | 1 | Sep 27, 2018 | clinicaltrials |
| NCT00859027 | Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer | completed | Phase 4 | 50 | UConn HealthOTHER | 1 | May 1, 2018 | clinicaltrials |
| NCT02025361 | Impact of Local Anesthesia Type on Cancer Detection Rate in Transrectal Ultrasound Guided Prostate Biopsy | completed | Phase 4 | 422 | Bagcilar Training and Research HospitalOTHER_GOV | 1 | Jan 18, 2018 | clinicaltrials |
| NCT01296672 | 3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer | completed | Phase 4 | 383 | The University of Texas Health Science Center at San AntonioOTHER | 1 | Oct 6, 2017 | clinicaltrials |
| NCT00063609 | The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy | completed | Phase 4 | 200 | Novartis PharmaceuticalsINDUSTRY | 1 | Sep 13, 2017 | clinicaltrials |
| NCT00219271 | Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer | completed | Phase 4 | 60 | Novartis PharmaceuticalsINDUSTRY | 1 | May 31, 2017 | clinicaltrials |
| NCT01230905 | Study to Monitor the Effects of Androgen Suppression Treatment on the Heart(AST) | completed | Phase 4 | 181 | Ottawa Heart Institute Research CorporationOTHER | 1 | Apr 24, 2017 | clinicaltrials |
| NCT00237146 | Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy | completed | Phase 4 | 38 | Novartis PharmaceuticalsINDUSTRY | 1 | Feb 23, 2017 | clinicaltrials |
| NCT00242554 | Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases | completed | Phase 4 | 150 | Novartis PharmaceuticalsINDUSTRY | 0 | Feb 23, 2017 | clinicaltrials |
| NCT00334139 | Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer | completed | Phase 4 | 411 | Novartis PharmaceuticalsINDUSTRY | 1 | Feb 7, 2017 | clinicaltrials |
| NCT02441894 | Combination of Cabazitaxel With Prednisolone With Primary Prophylaxis With PEG-G-CSF in Treatment of Patients With Prostate Cancer(PEGAZUS) | completed | Phase 4 | 21 | SanofiINDUSTRY | 1 | Jan 24, 2017 | clinicaltrials |
| NCT00375765 | Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer | completed | Phase 4 | 40 | GlaxoSmithKlineINDUSTRY | 1 | Jan 19, 2017 | clinicaltrials |
| NCT01571544 | The Use of Thermal Suits as Preventing Hypothermia During Surgery | completed | Phase 4 | 100 | Tampere University HospitalOTHER | 1 | Jan 4, 2017 | clinicaltrials |
| NCT00391690 | Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer | completed | Phase 4 | 99 | NovartisINDUSTRY | 1 | Nov 18, 2016 | clinicaltrials |
| NCT00220194 | A Six-Month, Open-Label, Crossover Study Of the Maintenance Of Serum Testosterone And PSA Suppression After Switching Between Lupron 22.5 Mg And Eligard 22.5 Mg Or Zoladex 10.8 Mg And Eligard 22.5 Mg In Patients With Advanced Prostate Cancer | completed | Phase 4 | 100 | San Bernardino Urological Associates Medical Group IncOTHER | 1 | Oct 14, 2016 | clinicaltrials |
| NCT01649635 | Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer(PROSPECTA) | completed | Phase 4 | 45 | SanofiINDUSTRY | 1 | Jul 6, 2016 | clinicaltrials |
| NCT02773251 | The Effect of Guardix-solution for the Prevention of Postoperative Intestinal Adhesion and Intestinal Obstruction After Laparoscopic Pelvic Cavity Surgery | completed | Phase 4 | 60 | Bucheon St. Mary's HospitalOTHER | 0 | May 17, 2016 | clinicaltrials |
| NCT01083199 | Global Performance Evaluation of the AMS CONTINUUM™ Device | completed | Phase 4 | 10 | American Medical SystemsINDUSTRY | 2 | Apr 12, 2016 | clinicaltrials |
| NCT02102646 | MRI Substudy; Metabolic Changes Due to Iatrogenic Hypogonadism | completed | Phase 4 | 31 | Herlev HospitalOTHER | 1 | Oct 28, 2015 | clinicaltrials |
| NCT01511874 | Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer | completed | Phase 4 | 42 | HanAll BioPharma Co., Ltd.INDUSTRY | 1 | Sep 23, 2015 | clinicaltrials |
| NCT02149628 | The Effect of Propofol Based Total Intravenous Anesthesia on Oxidative Stress and Nitric Oxide | completed | Phase 4 | 50 | Yonsei UniversityOTHER | 1 | Jul 29, 2015 | clinicaltrials |
| NCT00219219 | Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases | completed | Phase 4 | — | NovartisINDUSTRY | 1 | Apr 14, 2015 | clinicaltrials |
| NCT00805701 | Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation | completed | Phase 4 | 40 | Bay State Clinical Trials, Inc.OTHER | 1 | May 14, 2014 | clinicaltrials |
| NCT01486563 | Hydroxyethyl Starch and Renal Function After Radical Prostatectomy(VORA) | completed | Phase 4 | 40 | Regional Hospital HolstebroOTHER | 1 | Sep 17, 2013 | clinicaltrials |
| NCT01161563 | Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration | completed | Phase 4 | 118 | Watson PharmaceuticalsINDUSTRY | 1 | Sep 6, 2013 | clinicaltrials |
| NCT01547416 | The Effect of Combined General/Epidural Anesthesia Versus General Anesthesia on Diaphragmatic Function | completed | Phase 4 | 50 | Yonsei UniversityOTHER | 1 | Jul 11, 2013 | clinicaltrials |
| NCT00771966 | Radical Prostatectomy and Perioperative Fluid Therapy | completed | Phase 4 | 44 | Rigshospitalet, DenmarkOTHER | 1 | Oct 22, 2012 | clinicaltrials |
| NCT00029224 | Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions | completed | Phase 4 | 500 | NovartisINDUSTRY | 1 | Feb 1, 2012 | clinicaltrials |
| NCT00526331 | Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy | completed | Phase 4 | 49 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 16, 2012 | clinicaltrials |
| NCT00106392 | A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy | completed | Phase 4 | 131 | Astellas Pharma IncINDUSTRY | 1 | Nov 23, 2010 | clinicaltrials |
Data updated 22 days agoSource updated Jul 13, 2026source: clinicaltrials